PubRank

J G Rabkin

Author PubWeight™ 81.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Live events, stress, and illness. Science 1976 3.05
2 Wish to die in end-stage ALS. Neurology 2005 2.97
3 Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 1991 2.06
4 Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984 1.66
5 Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care 2000 1.56
6 Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991 1.40
7 Medical and dental students' attitudes about the AIDS epidemic. Acad Med 1990 1.32
8 Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993 1.26
9 Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry 1994 1.22
10 Hypertension and DSM-III depression in psychiatric outpatients. Am J Psychiatry 1983 1.20
11 Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am J Drug Alcohol Abuse 1999 1.20
12 Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry 1991 1.17
13 How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986 1.15
14 The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc 1999 1.15
15 Validity of clinical trials of antidepressants. Am J Psychiatry 2000 1.14
16 Ethnic density and psychiatric hospitalization: hazards of minority status. Am J Psychiatry 1979 1.10
17 Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull 1987 1.08
18 Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 2009 1.07
19 Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988 1.07
20 Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology 2004 1.03
21 Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998 1.02
22 Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988 1.01
23 The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med 1998 1.01
24 Atypical depression. A valid clinical entity? Psychiatr Clin North Am 1993 1.00
25 Hopelessness as a mediator of the association between social support and depressive symptoms: findings of a study of men with HIV. J Consult Clin Psychol 2001 0.96
26 Stressful life events and schizophrenia: a review of the research literature. Psychol Bull 1980 0.96
27 Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Compr Psychiatry 1999 0.93
28 Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry 1984 0.93
29 Study duration in antidepressant research: advantages of a 12-week trial. J Psychiatr Res 1986 0.93
30 Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics 2000 0.92
31 Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990 0.91
32 Axis I psychiatric symptoms associated with HIV infection and personality disorder. Am J Psychiatry 1995 0.91
33 Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year. J Acquir Immune Defic Syndr 1999 0.91
34 Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998 0.90
35 Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991 0.90
36 Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986 0.89
37 Bipolar disorder: are there manic-prone and depressive-prone forms? J Clin Psychopharmacol 1986 0.89
38 Opinions about mental illness: a review of the literature. Psychol Bull 1972 0.88
39 Sexual risk behavior changes among HIV+ and HIV-female injecting drug users over 4 years. Women Health 1998 0.88
40 Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997 0.88
41 Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacol 1993 0.88
42 A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993 0.87
43 A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Compr Psychiatry 1997 0.87
44 Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992 0.87
45 Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989 0.87
46 Mental health needs assessment. A review of methods. Med Care 1986 0.86
47 Criminal behavior of discharged mental patients: a critical apprasial of the research. Psychol Bull 1979 0.86
48 Treatment of premenstrual dysphoric changes: clinical outcome and methodological implications. Psychopharmacol Bull 1984 0.85
49 Loss of drug effects during continuation therapy. Am J Psychiatry 1993 0.85
50 Sexual activity among HIV-seropositive gay men seeking treatment for depression. J Clin Psychiatry 1993 0.84
51 Disease severity, physical limitations and depression in HIV-infected men. J Psychosom Res 1998 0.84
52 Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol Bull 1986 0.84
53 Sleep of atypical depressives. J Affect Disord 1985 0.83
54 Psychological and physical health correlates of body cell mass depletion among HIV+ men. J Psychosom Res 2000 0.83
55 What the neighbors think: community attitudes toward local psychiatric facilities. Community Ment Health J 1984 0.82
56 Treating depression in HIV-positive patients. AIDS 1994 0.82
57 Development of the Impact of Weight Loss Scale (IWLS): a psychometric study in a sample of men with HIV/AIDS. AIDS Care 1999 0.82
58 Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993 0.82
59 Stability and change in personality disorder symptomatology: findings from a longitudinal study of HIV+ and HIV- men. J Abnorm Psychol 1997 0.82
60 Defining the boundaries of atypical depression. J Clin Psychiatry 1984 0.81
61 A female perspective on living with HIV disease. Health Soc Work 2001 0.81
62 Personality disorders predict onset of Axis I disorders and impaired functioning among homosexual men with and at risk of HIV infection. Arch Gen Psychiatry 1996 0.81
63 Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.81
64 Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 1999 0.80
65 Adhering to complex regimens for HIV. GMHC Treat Issues 1998 0.80
66 Remission of substance use disorders: gay men in the first decade of AIDS. J Stud Alcohol 1995 0.79
67 Follow-up of patients who improved during placebo washout. J Clin Psychopharmacol 1986 0.79
68 Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Res 1987 0.79
69 Psychological aspects of living with HIV disease: a primary care perspective. West J Med 2001 0.79
70 Bereavement reactions among homosexual men experiencing multiple losses in the AIDS epidemic. Am J Psychiatry 1992 0.78
71 Psychiatric evaluation of premenstrual changes. Psychosomatics 1985 0.78
72 Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985 0.78
73 Measuring medication adherence: is assessment of missed doses sufficient? AIDS 1999 0.78
74 Psychological distress and natural killer cells in gay men with and without HIV infection. Am J Psychiatry 1994 0.78
75 Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics 1989 0.77
76 Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment. Psychiatry Res 1988 0.77
77 l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984 0.77
78 Health locus of control, distress, and utilization of protease inhibitors among HIV-positive men. J Psychosom Res 2000 0.77
79 Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989 0.77
80 Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol 1985 0.76
81 Testosterone as a treatment for fatigue in HIV+ men. Gen Hosp Psychiatry 1998 0.76
82 Methodological problems in studies of depressive disorder: utility of the discontinuation design. J Clin Psychopharmacol 1981 0.76
83 Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS. Int J STD AIDS 1998 0.76
84 Who is called mentally ill: public and professional views. J Community Psychol 1979 0.76
85 The concurrent validity of items in the Quality-of-Life Index in a cohort of HIV-positive and HIV-negative gay men. Control Clin Trials 1991 0.75
86 Factors associated with premature medication discontinuation among responders to an MAOI or a tricyclic antidepressant. J Clin Psychiatry 1988 0.75
87 Kaposi's sarcoma: The Scarlet Letter of AIDS: the psychological effects of a skin disease. Psychosomatics 2000 0.75
88 Evaluation of a mental health consultation service in a ghetto area. Am J Psychother 1970 0.75
89 The dexamethasone suppression test with mildly to moderately depressed outpatients. Am J Psychiatry 1983 0.75
90 Long-term testosterone therapy in HIV-positive men: side-effects and maintenance of clinical benefit. AIDS 1998 0.75
91 Psychopharmacologic validation of atypical depression. J Clin Psychiatry 1984 0.75
92 Testosterone, illness progression, and megestrol use in HIV-positive men. J Acquir Immune Defic Syndr Hum Retrovirol 1998 0.75
93 Validity assessment of SAFTEE: a preliminary report. Psychopharmacol Bull 1987 0.75
94 The epidemiology of forcible rape. Am J Orthopsychiatry 1979 0.75
95 Effects of testosterone upon body composition. J Acquir Immune Defic Syndr Hum Retrovirol 1996 0.75
96 Mianserin versus amitriptyline for depression: a double-blind 6-week trial. Neuropsychobiology 1984 0.75
97 Attrition and its consequences in a clinical trial of placebo, imipramine, and phenelzine. Psychopharmacol Bull 1985 0.75
98 Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology 1985 0.75
99 Difficulties in interpersonal relationships associated with personality disorders and axis I disorders: a community-based longitudinal investigation. J Pers Disord 2000 0.75
100 Cortisol response to dextroamphetamine stimulation in depressed outpatients. Psychiatry Res 1984 0.75
101 Immunologic effects of psychotropic drugs in HIV+ patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996 0.75
102 Psychopharmacological dissection of nonendogenous depression. Psychopharmacol Bull 1984 0.75